CAS 4929-23-1

Formule : C15H14ClN3O

InChI : InChI=1S/C15H14ClN3O/c1-2-8-19-13-4-3-7-17-14(13)18-12-9-10(16)5-6-11(12)15(19)20/h3-7,9H,2,8H2,1H3,(H,17,18)

Code InChI : QTCZUCSALXBZQR-UHFFFAOYSA-N

SMILES : CCCN1C2=C(NC3=C(C1=O)C=CC(=C3)Cl)N=CC=C2

BI-0115

CAS : 4929-23-1

BI-0115

Formule : C₁₅H₁₄ClN₃O

Degré de pureté : ≥98%

Masse moléculaire : 287.74

Ref: 54-BUP03166

BI-0115

CAS : 4929-23-1

Formule : C₁₅H₁₄ClN₃O

Masse moléculaire : 287.7442

Ref: IN-DA01V440

BI-0115

CAS : 4929-23-1

BI-0115 inhibits LOX-1, preventing oxLDL uptake by triggering receptor inhibition and dimer formation.

Formule : C₁₅H₁₄ClN₃O

Degré de pureté : 99.34%

Couleur et forme : Yellow Solid

Masse moléculaire : 287.744

Ref: TM-T9108

9-Chloro-5,11-dihydro-5-propyl-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one

CAS : 4929-23-1

BI-0115 is a highly selective inhibitor for the lectin-like oxidised low-density lipoproteins (LDL) receptor 1 (LOX-1). In vitro, BI-0115 inhibits internalisation of oxidised LDL (oxLDL) with IC50 of 5.4?µM. The crystal studies revealed that BI-0115 glues two LOX-1 dimers together, resulting in blocked access of oxLDL. LOX-1 is a Ctype lectin-like receptor expressed on endothelial cells, macrophages and vascular smooth muscle. It is responsible for the regulation, internalisation and degradation of oxidised low-density lipoproteins (oxLDL). BI-0115 is a novel inhibitor to LOX-1 and is a valuable tool to study LOX-1 biology, and their role in diseases, such as, cancer and atheroschelerosis.

Formule : C₁₅H₁₄ClN₃O

Degré de pureté : Min. 98 Area-%

Couleur et forme : Yellow Powder

Masse moléculaire : 287.87 g/mol

Ref: 3D-BB178547

9-Chloro-5,11-dihydro-5-propyl-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one

Produit contrôlé

CAS : 4929-23-1

Formule : C₁₅H₁₄ClN₃O

Couleur et forme : Neat

Masse moléculaire : 287.744

Ref: TR-C492920